Top 5 bladder cancer articles of 2019

The priority review decision is based on results of the phase 3 NIAGARA study (NCT03732677).

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” says Arnold I. Chin, MD, PhD.

“When you compound the patient delay and…the physician delay, then you really get a delay in diagnosis,” says Curtis A. Pettaway, MD.

The study showed significant reductions in both anxiety and depressive symptoms following the intervention.

At the time of data cutoff, 71% of patients achieved a complete response following treatment.